untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:33:10Z</responseDate>
<request identifier=oai:HAL:hal-00875175v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-00875175v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-PARIS5</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:CESP</setSpec>
<setSpec>collection:UNIV-PSUD</setSpec>
<setSpec>collection:UVSQ</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.</title>
<creator>Goujard, Cécile</creator>
<creator>Emilie, Dominique</creator>
<creator>Roussillon, Caroline</creator>
<creator>Godot, Véronique</creator>
<creator>Rouzioux, Chrisitine</creator>
<creator>Venet, Alain</creator>
<creator>Colin, Céline</creator>
<creator>Pialoux, Gilles</creator>
<creator>Girard, Pierre-Marie</creator>
<creator>Boilet, Valérie</creator>
<creator>Chaix, Marie-Laure</creator>
<creator>Galanaud, Pierre</creator>
<creator>Chene, Geneviève</creator>
<creator>Michelet, Christian</creator>
<contributor>Service de médecine interne et maladies infectieuses ; Université Paris-Sud - Paris 11 (UP11) - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Bicêtre</contributor>
<contributor>Centre de recherche en épidémiologie et santé des populations (CESP) ; Université de Versailles Saint-Quentin-en-Yvelines (UVSQ) - Université Paris-Sud - Paris 11 (UP11) - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Paul Brousse - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Cytokines, chimiokines et immunopathologie ; Université Paris-Sud - Paris 11 (UP11) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Epidémiologie et Biostatistique [Bordeaux] ; Université Bordeaux Segalen - Bordeaux 2 - Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Laboratoire de Virologie [CHU Necker] ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Necker - Enfants Malades [AP-HP]</contributor>
<contributor>Régulation de la réponse immune, infection VIH-1 et autoimmunité ; Université Paris-Sud - Paris 11 (UP11) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service des maladies infectieuses et tropicales ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Tenon [APHP]</contributor>
<contributor>Service des maladies infectieuses et tropicales [CHU Saint-Antoine] ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Saint-Antoine [APHP]</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>French National Agency forResearch on AIDS and ViralHepatitis (ANRS)</contributor>
<description>International audience</description>
<source>ISSN: 0269-9370</source>
<source>AIDS</source>
<publisher>Lippincott, Williams & Wilkins</publisher>
<identifier>hal-00875175</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-00875175</identifier>
<source>https://hal.archives-ouvertes.fr/hal-00875175</source>
<source>AIDS, Lippincott, Williams & Wilkins, 2012, 26 (15), pp.1895-905. 〈10.1097/QAD.0b013e32835844d9〉</source>
<identifier>DOI : 10.1097/QAD.0b013e32835844d9</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/QAD.0b013e32835844d9</relation>
<identifier>PUBMED : 22842994</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/22842994</relation>
<language>en</language>
<subject lang=en>antiretroviral treatment</subject>
<subject lang=en>HIV-1</subject>
<subject lang=en>interferon</subject>
<subject lang=en>primary infection</subject>
<subject lang=en>treatment interruption</subject>
<subject>[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>OBJECTIVES: The ANRS-112 INTERPRIM trial assessed whether fixed-cycles of antiretroviral treatment interruption (ART-STI) combined or not with pegylated interferon alpha-2b (peg-IFN) could lower viral load and achieve a healthier immune system in patients diagnosed during primary HIV-1-infection (PHI). DESIGN AND METHODS: Patients were randomized to receive either continuous ART (cART) during 72 weeks, or cART during 36 weeks followed by three ART-STIs, or the same ART-STIs associated with peg-IFN during the first 14 weeks and each interruption (ART-STI-IFN). Treatment was stopped at week 72. Final evaluation was based on plasma HIV-RNA level 6 months after the last treatment interruption. RESULTS: Eighty-seven percent of patients achieved undetectable HIV-RNA at week 32, with no deleterious impact of sequential treatment interruptions (STIs). Viral rebounds during interruptions were lower in the ART-STI-IFN than in the ART-STI group and during the second and third interruptions compared with the first one. However, HIV-RNA levels, CD4 T-cell counts and CD4 T/CD8 T ratios were similar between groups after the 6-month interruption, with a persistent effect on CD4 T cells and total cell-associated HIV-DNA levels. Predictive factors of virological outcome were HIV-RNA and HIV-DNA levels at PHI and HIV-DNA levels at treatment interruption. HIV-specific responses did not differ between strategies and were not associated with outcome. Forty-eight percent of patients experienced treatment resumption during long-term follow-up without difference between groups. CONCLUSION: When initiated during PHI, STIs associated or not with IFN did not result in a different outcome as compared to cART. All regimens showed a high response rate and a sustained immunological benefit after cessation.</description>
<contributor>ANRS-112 INTERPRIM Study Group</contributor>
<date>2012-09-24</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
